KPTI Live signals | Maximize Profits with Getagraph.com

BUY 157646 min ago

@ $1.418

Issued: 14 Feb 2024 @ 15:43

Return: -31.66%

Previous signal: Feb 13 - 12:41

Previous signal: Sell

Return: 12.54 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Stats
Today's Volume	1.24M
Average Volume	1.23M
Market Cap	114.07M
EPS	$0 ( 2024-05-08 )
Next earnings date	( $-0.320 ) 2024-08-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.760
ATR14	$0.00200 (0.21%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-29	Su Zhen	Buy	50 587	Nonstatutory Stock Option (right to buy)
2024-05-29	Schor Chen	Buy	69 000	Nonstatutory Stock Option (right to buy)
2024-05-29	Pakianathan Deepika	Buy	69 000	Nonstatutory Stock Option (right to buy)
2024-05-29	Oliger Christy J.	Buy	69 000	Nonstatutory Stock Option (right to buy)
2024-05-29	Mirza Mansoor Raza	Buy	69 000	Nonstatutory Stock Option (right to buy)

INSIDER POWER
76.07
Last 99 transactions
Buy: 3 224 022 \| Sell: 433 207

Volume Correlation

Long: 0.33 (neutral)

Short: 0.07 (neutral)

Signal:(50.08) Neutral

Karyopharm Therapeutics Correlation

10 Most Positive Correlations
RDCM	0.883
LANC	0.857
EOLS	0.845
VXRT	0.84
KURA	0.839
CGEN	0.835
CACG	0.834
ASML	0.831
GNTX	0.827
PXLW	0.827

10 Most Negative Correlations
GSM	-0.833
OSBC	-0.811
CSSEP	-0.805

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Karyopharm Therapeutics Correlation - Currency/Commodity

0.00
( neutral )

0.04
( neutral )

-0.21
( neutral )

Karyopharm Therapeutics Financials

Annual	2023
Revenue:	$146.03M
Gross Profit:	$140.56M (96.25 %)
EPS:	$-1.250

FY	2023
Revenue:	$146.03M
Gross Profit:	$140.56M (96.25 %)
EPS:	$-1.250

FY	2022
Revenue:	$157.07M
Gross Profit:	$151.86M (96.68 %)
EPS:	$-2.02

FY	2021
Revenue:	$209.82M
Gross Profit:	$206.42M (98.38 %)
EPS:	$-1.650

Financial Reports:

No articles found.

Karyopharm Therapeutics Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Karyopharm Therapeutics

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.